The wide use of lamivudine (3TC) as oral therapy for chronic HBV infection has favoured the selection and circulation of 3TC-resistant HBV strains worldwide. Although transmission of 3TC-resistant HBV variants has been reported only sporadically, few studies have been conducted in the HIV population where exposure to 3TC has been greater forming part of antiretroviral therapy (ART) regimens.
Methods
All individuals positive for serum hepatitis B surface antigen (HBsAg), newly diagnosed with HIV-1 infection, naive to ART and enrolled in the Spanish HIV cohort (CoRIS) since 2004 were identified. The HBV polymerase gene was sequenced and drug resistance mutations were characterized retrospectively in stored frozen plasma specimens.
Results
From 4,419 ART-naive HIV-1-infected individuals, 223 (5.1%) were positive for serum HBsAg. Baseline stored sera were available for 84 patients, of whom 73 could be characterized virologically. This population was mainly represented by men who had sex with men (52.1%), native Spaniards (65.7%) and Latin Americans (16.4%). The mean age was 36 years, mean CD4+ T-cell count 375 cells/mm3 and mean plasma HIV RNA 4.5 log10 copies/ml. The HBV genotype distribution was 64% A, 20% F, 12% D and 4% others. Drug-resistant mutations in the HBV polymerase were found in four (5.5%) patients: two harboured rtL180M, one rtL80V and one rtV173L.
Conclusions
The rate of primary drug resistance in HBV among newly diagnosed HIV–HBV-coinfected patients in Spain is currently low (5.5%) and restricted to 3TC. Thus, HBV drug resistance testing before prescription of oral antiviral therapy is not warranted, although periodic surveillance might be recommended.
References
1.
AlterM.J.Epidemiology of viral hepatitis and HIV co-infection. J Hepatol2006; 44Suppl 1: S6–S9.
2.
LokA.S., McMahonB.Chronic hepatitis B. Hepatology2007; 45: 507–539.
3.
VallejoF., ToroC., de la FuenteL.Hepatitis B vaccination: an unmet challenge in the era of harm reduction programs. J Subst Abuse Treat2008; 34: 398–406.
4.
ZoulimF., LocarniniS.Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology2009; 137: 1593–1608.
5.
SheldonJ., SorianoV.Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother2008; 61: 766–768.
6.
ClementsC.J., CoghlanB., CreatiM., LocarniniS., TedderR., TorresiJ.Global control of HBV: does treatment-induced antigenic change affect immunization?Bull World Health Organ2010; 88: 66–73.
7.
ThibaultV., Aubron-OlivierC., AgutH., KatlamaC.Primary infection with a lamivudine-resistant hepatitis B virus. AIDS2002; 16: 131–133.
8.
LudwigA., GoebelT., AdamsO.Primary resistance mutations against nucleos(t)ide analogues in treatment naïve patients with HBV infection.American Association for the Study of Liver Diseases. 31 October – 4 November 2008, San Francisco, CA, USA. Abstract 884.
9.
FungS., MazulliT., El-KashabM., ShermanM., PopovicV.Lamivudine-resistant mutation among treatment-naive hepatitis B patients is common and may be associated with treatment failure.American Association for the Study of Liver Diseases. 31 October – 4 November 2008, San Francisco, CA, USA. Abstract 888.
10.
XuZ., LiuY., XuT.Acute hepatitis B infection associated with drug resistant hepatitis B virus. J Clin Virol2010; 48: 270–274.
11.
BenhamouY., BochetM., ThibaultV.Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology1999; 30: 1302–1306.
12.
Caro-MurilloA.M., CastillaJ., Perez-HoyosS.Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results. Enferm Infecc Microbiol Clin2007; 25: 23–31.
13.
García-MerinoI., de Las CuevasN., JiménezJ.L.The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology2009; 6: 27.
14.
MatthewsG.V., BartholomeuszA., LocarniniS.Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS2006; 20: 863–870.
Servant-DelmasA., MercierM., El GhouzziM.National survey of HBV polymorphisms in asymptomatic HBV blood donors from 1999 to 2007 in France. Transfusion2010; 50: 2607–2618.
17.
Rodriguez-FriasF., JardiR., SchaperM.Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. Antivir Ther2008; 13: 991–999.
18.
BottecchiaM., MadejonA., SheldonJ., Garcia-SamaniegoJ., BarreiroP., SorianoV.Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. J Antimicrob Chemother2008; 62: 626–627.
19.
SloanR.D., StrangA., RamsayM., TeoC.Genotyping of acute HBV isolates from England, 1997-2001. J Clin Virol2009; 44: 157–160.
20.
SorianoV., MocroftA., PetersL.Predictors of HBV genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother2010; 65: 548–555.
21.
TreviñoA., SorianoV., MadejonA.Transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals. AIDS Res Hum Retroviruses2009; 25: 1273–1276.
22.
WongprasitP., ManosutheM., KiertiburanakulS., SungkanuparhS.Hepatitis B virus drug resistance in HIV-infected patients taking lamivudine-containing antiretroviral therapy. AIDS Patient Care STDS2010; 24: 205–209.
23.
Margeridon-ThermetS., ShulmanN., AhmedA.Ultra-deep pyrosequencing of HBV quasispecies from nucleoside and nucleotide reverse transcriptase inhibitor (NRTI)-treated patients and NRTI-naïve patients. J Infect Dis2009; 199: 1275–1285.
24.
HirschM.S., GunthardH., SchapiroJ.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis2008; 47: 266–285.
25.
SorianoV., RivasP., NuñezM.Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis2008; 47: 1486–1489.
26.
HoffmannC.J., CharalambousS., MartinD.Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis2008; 47: 1479–1485.
27.
ThioC.L., LocarniniS.Treatment of HIV/HBV coinfection: clinical and virologic issues. AIDS Rev2007; 9: 40–53.
